| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004184 | American Journal of Ophthalmology | 2009 | 10 Pages |
Abstract
Considerable variability exists in how bevacizumab is used for the treatment of ROP in the literature to date. Further randomized control trials are warranted and should aim to assess statistically the optimal timing, frequency, and dose of the drug. Careful attention should be given to the potential for systemic complications and long-term effects of intravitreal bevacizumab in infants.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jonathan A. Micieli, Michael Surkont, Andrew F. Smith,